Related Experiment Video
Updated: Jun 15, 2026
07:51
Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
American heart association, 2009 scientific sessions
P & T : a Peer-Reviewed Journal for Formulary Management
|February 26, 2010
Summary
The ARBITER 6-HALTS study investigated lipid treatment strategies. Findings on lipid effects on cardiovascular disease and cancer were presented at the American Heart Association 2009 Scientific Sessions.
Area of Science:
- Cardiology
- Clinical Trials
- Lipid Metabolism
Background:
- The American Heart Association (AHA) 2009 Scientific Sessions convened in Orlando, Florida.
- Key research presented included late-breaking clinical trials and sessions on cardiovascular disease and cancer.
Purpose of the Study:
- To provide an overview of significant findings from the AHA 2009 Scientific Sessions.
- To highlight the ARBITER 6-HALTS lipid treatment strategy study.
- To cover trials on angiotensin-receptor blockers in heart failure and lipid effects on cardiovascular disease and cancer.
Main Methods:
- Review of late-breaking clinical trial presentations.
- Analysis of sessions examining lipid effects on cardiovascular disease and cancer.
- Coverage of a clinical trial on angiotensin-receptor blockers for heart failure.
Main Results:
- The ARBITER 6-HALTS lipid treatment strategy study generated significant attention and controversy.
- Clinical trials explored the impact of lipids on cardiovascular disease and cancer.
- Angiotensin-receptor blockers were evaluated in the context of heart failure.
Conclusions:
- The AHA 2009 Scientific Sessions showcased critical advancements in cardiovascular research.
- Lipid management remains a key focus in cardiovascular disease prevention and treatment.
- Further research is needed to understand the complex relationship between lipids, cardiovascular health, and cancer.
Related Concept Videos
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:17Ischemic Heart Disease: Overview
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...